Biogen (BIIB) and Stoke Therapeutics (STOK) announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society, AES, Annual Meeting in Atlanta, Georgia. Long-term Phase 1/2a and open label extension data for zorevunersen on top of standard of care anti-seizure medicines demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life. Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and consistent with the ongoing Phase 3 EMPEROR study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Eisai, Biogen say Leqembi data suggests potential to delay disease progression
- Biogen/Eisai present new Alzheimer’s Disease clinical trial data at CTAD
- Eisai files new drug application for subcutaneous Leqembi in Japan
- Eisai completes rolling submission of sBLA for Leqembi Iqlik to FDA
- Biogen’s Strategic Advantage: Buy Rating Amid Competitive Shifts and Promising Pipeline Developments